JP2015509500A - 眼疾患を予防または治療するための方法および組成物 - Google Patents

眼疾患を予防または治療するための方法および組成物 Download PDF

Info

Publication number
JP2015509500A
JP2015509500A JP2014558832A JP2014558832A JP2015509500A JP 2015509500 A JP2015509500 A JP 2015509500A JP 2014558832 A JP2014558832 A JP 2014558832A JP 2014558832 A JP2014558832 A JP 2014558832A JP 2015509500 A JP2015509500 A JP 2015509500A
Authority
JP
Japan
Prior art keywords
phe
lys
arg
dmt
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014558832A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015509500A5 (enExample
Inventor
ディー トラヴィス ウィルソン
ディー トラヴィス ウィルソン
ケイ ジョージ ムーニー
ケイ ジョージ ムーニー
ピーター ジェイ オーツ
ピーター ジェイ オーツ
Original Assignee
ステルス ペプチドズ インターナショナル インコーポレイテッド
ステルス ペプチドズ インターナショナル インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ステルス ペプチドズ インターナショナル インコーポレイテッド, ステルス ペプチドズ インターナショナル インコーポレイテッド filed Critical ステルス ペプチドズ インターナショナル インコーポレイテッド
Publication of JP2015509500A publication Critical patent/JP2015509500A/ja
Publication of JP2015509500A5 publication Critical patent/JP2015509500A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2014558832A 2012-02-22 2013-02-21 眼疾患を予防または治療するための方法および組成物 Pending JP2015509500A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261601878P 2012-02-22 2012-02-22
US61/601,878 2012-02-22
US201261605576P 2012-03-01 2012-03-01
US61/605,576 2012-03-01
PCT/US2013/027175 WO2013126597A1 (en) 2012-02-22 2013-02-21 Methods and compositions for preventing or treating ophthalmic conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017111746A Division JP2017214380A (ja) 2012-02-22 2017-06-06 眼疾患を予防または治療するための方法および組成物

Publications (2)

Publication Number Publication Date
JP2015509500A true JP2015509500A (ja) 2015-03-30
JP2015509500A5 JP2015509500A5 (enExample) 2016-04-07

Family

ID=49006208

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014558832A Pending JP2015509500A (ja) 2012-02-22 2013-02-21 眼疾患を予防または治療するための方法および組成物
JP2017111746A Pending JP2017214380A (ja) 2012-02-22 2017-06-06 眼疾患を予防または治療するための方法および組成物
JP2018189741A Pending JP2019034947A (ja) 2012-02-22 2018-10-05 眼疾患を予防または治療するための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017111746A Pending JP2017214380A (ja) 2012-02-22 2017-06-06 眼疾患を予防または治療するための方法および組成物
JP2018189741A Pending JP2019034947A (ja) 2012-02-22 2018-10-05 眼疾患を予防または治療するための方法および組成物

Country Status (8)

Country Link
US (3) US20150018288A1 (enExample)
EP (4) EP3078384A1 (enExample)
JP (3) JP2015509500A (enExample)
CN (2) CN105343869A (enExample)
AU (3) AU2013222423A1 (enExample)
CA (1) CA2865317A1 (enExample)
HK (1) HK1204988A1 (enExample)
WO (1) WO2013126597A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10793597B2 (en) * 2013-03-01 2020-10-06 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial diseases associated with a mutation in SURF 1 or POLG gene resulting in a disruption of mitochondrial oxidative phosphorylation
EP3626252A1 (en) 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
US10047395B2 (en) 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
US20160193278A1 (en) * 2013-08-01 2016-07-07 Stealth Biotherapeutics Corp Methods and compositions for preventing or treating leber's hereditary optic neuropathy
CN106132984B (zh) * 2013-12-27 2020-12-08 康德生物医疗技术公司 药学相关的芳香族阳离子肽
US20160317606A1 (en) * 2014-01-06 2016-11-03 Stealth Bio Therapeutics Corp Methods and compositions for preventing or treating dominant optic atrophy
CN106459169A (zh) * 2014-03-03 2017-02-22 康德生物医疗技术公司 药学上相关的芳香族阳离子肽
EP3113613A4 (en) * 2014-03-03 2019-03-13 Encore Vision, Inc. LIPOIC ACID CHOLINESTER COMPOSITIONS AND METHOD OF USE THEREOF
JP6854771B2 (ja) 2015-03-06 2021-04-07 ステルス バイオセラピューティックス コープ 薬学的に適切なペプチドを調製するための方法
WO2017156403A1 (en) 2016-03-11 2017-09-14 Stealth Biotherapeutics Crystalline salt forms
US10870678B2 (en) 2016-04-11 2020-12-22 Arcuate Therapeutics, Inc. Chiral peptides
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
JP7636334B2 (ja) * 2019-02-08 2025-02-26 オハイオ・ステイト・イノベーション・ファウンデーション 治療物質の眼投与のための薬物送達組成物及びその使用法
EP3771467A1 (en) * 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm
CA3180714A1 (en) * 2020-04-23 2021-10-28 Okogen, Inc. Treatment of viral conjunctivitis
KR102429281B1 (ko) * 2020-05-25 2022-08-05 (주)노바셀테크놀로지 신규 안구건조증 치료용 약학적 조성물
US20240209038A1 (en) * 2021-07-01 2024-06-27 The Regents Of The University Of California Targeting piezo1 to treat inherited and age-related macular degenerations
CN113975402B (zh) * 2021-07-19 2023-05-16 河南大学 靶向脑缺血区线粒体的神经保护药物ss31-ha-qt及其荧光探针和应用
WO2023069549A1 (en) * 2021-10-20 2023-04-27 Stealth Biotherapeutics Inc. Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
CN115252555B (zh) * 2022-06-07 2023-11-21 西安电子科技大学 一种膜融合性脂质体、制备方法及其在蛋白质递送中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002506028A (ja) * 1998-03-13 2002-02-26 ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン 糖尿病性網膜症または眼炎症の処置におけるゲニステインのようなタンパク質チロシンインヒビターの使用
JP2011500683A (ja) * 2007-10-19 2011-01-06 サーコード コーポレーション 糖尿病性網膜症の治療のための組成物及び方法
WO2011025734A1 (en) * 2009-08-24 2011-03-03 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
WO2011069046A1 (en) * 2009-12-04 2011-06-09 Euclid Systems Corporation Composition and methods for the prevention and treatment of macular degeneration, diabetic retinopathy, and diabetic macular edema

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US781405A (en) 1903-09-03 1905-01-31 Marcus A Coykendall Blank for dental plates.
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6217896B1 (en) 1999-04-01 2001-04-17 Uab Research Foundation Conjunctival inserts for topical delivery of medication or lubrication
CA3024434A1 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
EP3725324A1 (en) * 2005-09-16 2020-10-21 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing cd36 expression
EP2712620A1 (en) * 2008-02-07 2014-04-02 Cornell University Methods for Preventing or Treating Insulin Resistance
US20100081707A1 (en) * 2008-02-21 2010-04-01 Ali Robin R Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea
CN107802821A (zh) * 2008-02-26 2018-03-16 康奈尔大学 用于防止和治疗急性肾损伤的方法
CN103249423A (zh) * 2010-07-09 2013-08-14 康肽德生物医药技术有限公司 预防或治疗缺血/再灌注损伤之后无复流的方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002506028A (ja) * 1998-03-13 2002-02-26 ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン 糖尿病性網膜症または眼炎症の処置におけるゲニステインのようなタンパク質チロシンインヒビターの使用
JP2011500683A (ja) * 2007-10-19 2011-01-06 サーコード コーポレーション 糖尿病性網膜症の治療のための組成物及び方法
WO2011025734A1 (en) * 2009-08-24 2011-03-03 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
WO2011069046A1 (en) * 2009-12-04 2011-06-09 Euclid Systems Corporation Composition and methods for the prevention and treatment of macular degeneration, diabetic retinopathy, and diabetic macular edema

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE MERCK MANUALS ONLINE MEDICAL LIBRALY [ONLINE], 2005, JPN6016047321, ISSN: 0003456067 *

Also Published As

Publication number Publication date
US20150018288A1 (en) 2015-01-15
EP2817018A1 (en) 2014-12-31
JP2017214380A (ja) 2017-12-07
EP3479839A1 (en) 2019-05-08
CN104244964A (zh) 2014-12-24
US20180296630A1 (en) 2018-10-18
HK1204988A1 (en) 2015-12-11
CA2865317A1 (en) 2013-08-29
EP2817018A4 (en) 2015-09-23
EP3078384A1 (en) 2016-10-12
AU2017254849A1 (en) 2017-11-16
WO2013126597A1 (en) 2013-08-29
EP3281634A1 (en) 2018-02-14
AU2019203713A1 (en) 2019-06-20
AU2013222423A1 (en) 2014-09-11
JP2019034947A (ja) 2019-03-07
CN105343869A (zh) 2016-02-24
US20160361377A1 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
JP7642965B2 (ja) 眼疾患を予防または治療するための方法および組成物
JP2017214380A (ja) 眼疾患を予防または治療するための方法および組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170307

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171004